tirzepatide for heart health Lilly says weight loss drug cuts failure risk by 38% in trial Mounjaro, Zepbound Lowers Risk of

By combining exceptional innovation, product development capabilities, and an extensive global distribution network, GNC manages a best-in-class product portfolio

FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks

*For patients, out-of-pocket costusually in the form of a co-insurance percentage of the list priceis not the only factor determining their preferred choice of Humira-reference biosimilar

Product and Segment View Semaglutide holds 46% of molecule segment share in 2026,emergingas the leading segment due to its strong clinical efficacy in weight loss andestablishedtherapeutic positioning